These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 26933926)

  • 1. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to metronomic chemotherapy and ways to overcome it.
    Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
    Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metronomic chemotherapy in 2011: update and perspectives].
    Benbrahim Z; Massard C; El Mesbahi O
    Bull Cancer; 2011 Dec; 98(12):1447-54. PubMed ID: 22146261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 10. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
    Hida K; Kikuchi H; Maishi N; Hida Y
    Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Dec; 7(12):3670-84. PubMed ID: 19074844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
    Wu XY; Ma W; Gurung K; Guo CH
    J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic therapy: chemotherapy revisited.
    Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
    Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.
    Seidi K; Jahanban-Esfahlan R; Zarghami N
    Tumour Biol; 2017 Mar; 39(3):1010428317691001. PubMed ID: 28351332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the tumor stroma in cancer therapy.
    Anton K; Glod J
    Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
    Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
    J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of vascular disrupting agents and ionizing radiation.
    Clémenson C; Chargari C; Deutsch E
    Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.